Uncategorized
February 25, 2026
We often hear that modern science has "doubled" the human lifespan. We look at the statistics from 1840—where life expectancy was a mere 40 years—and compare them to our 80-year average today, assuming we’ve fundamentally reengineered human biology.
But the data tells a different, more sobering story.
February 20, 2026
Short answer: an FDA regulatory pathway is not just a compliance decision. It is a portfolio risk signal. For investors, the difference between 510(k), De Novo, […]
February 18, 2026
Short answer: incorrect FDA pathway assumptions don’t usually fail at the beginning. They fail when investors start asking hard questions. Early on, optimism hides regulatory gaps. During investor diligence, those gaps get exposed. That’s because regulatory pathway decisions—510(k), De Novo, or PMA—are not just technical. They define your timeline, capital needs, and exit strategy.
February 17, 2026
Straight answer: device classification controls how much evidence you must generate—and that controls how fast (or slow) you reach market. If you don’t understand your classification early, your timeline is not a plan. It’s a guess. Under the framework of the U.S. Food and Drug Administration, medical devices are placed into three risk-based classes: Class I, Class II, and Class III. The higher the risk, the heavier the evidence burden—and the longer the timeline.
